§ 01 Overview
Overview
Intestinotrophic peptide that stimulates intestinal growth and nutrient absorption; approved analog teduglutide is used in short bowel syndrome.
Teduglutide (GLP-2 analog) FDA-approved for short bowel syndrome.
§ 02 Mechanism
Mechanism of action
GLP-2 binds the GLP-2 receptor on enteric neurons and subepithelial myofibroblasts, stimulating epithelial proliferation, reducing intestinal permeability, and improving nutrient absorption.
- 01Intestinal mucosal growth and repair
- 02Reduced gut permeability
- 03Adjunct in IBD and gut-recovery protocols
§ 03 Dosing
Dosing protocol
Standard Protocol
- Dose Range
- 500 mcg – 1.5 mg daily (research)
- Route
- SubQ
- Frequency
- Daily
- Cycle
- 4–8 weeks for gut-recovery protocols
§ 04 Evidence
Evidence & research
Teduglutide (GLP-2 analog) FDA-approved for short bowel syndrome.
FDA Status
Teduglutide is FDA-approved. Non-analog GLP-2 is not.
§ 05 Stacks
Common stacks
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
GLP-1s, GLP-2s and "GLP-3s": What To Know And Which Actually Support Weight Loss - Forbes
GLP-1s, GLP-2s and "GLP-3s": What To Know And Which Actually Support Weight Loss Forbes
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies - Scripps Research
Calibr-Skaggs advances CLF065, a regenerative GLP-2 therapy, into two Phase 2 IBD studies Scripps Research
Hanmi Pharmaceutical Licenses GLP-2 Drug Candidate to Eli Lilly in $1.26 Billion Deal - Seoul Economic Daily
Hanmi Pharmaceutical Licenses GLP-2 Drug Candidate to Eli Lilly in $1.26 Billion Deal Seoul Economic Daily
Lilly licenses Hanmi’s GLP-2 biologic sonefpeglutide for $1.2bn - European Pharmaceutical Review
Lilly licenses Hanmi’s GLP-2 biologic sonefpeglutide for $1.2bn European Pharmaceutical Review
Eli Lilly Signs Up to $1.2B Licensing Deal for Hanmi GLP-2 Therapy in Short Bowel Syndrome - BioPharm International
Eli Lilly Signs Up to $1.2B Licensing Deal for Hanmi GLP-2 Therapy in Short Bowel Syndrome BioPharm International
Eli Lilly Bets 1.9 Trillion Won on Hanmi's GLP-2 Drug - Seoul Economic Daily
Eli Lilly Bets 1.9 Trillion Won on Hanmi's GLP-2 Drug Seoul Economic Daily
Hanmi licenses GLP-2 drug to Lilly in $1.26b deal, keeps Korea rights - CHOSUNBIZ - Chosunbiz
Hanmi licenses GLP-2 drug to Lilly in $1.26b deal, keeps Korea rights - CHOSUNBIZ Chosunbiz
Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate - BioSpace
Lilly maintains deal streak with $1.2B pact for Hanmi’s GLP-2 candidate BioSpace
§ 07 Sourcing
Sourcing & supply
Regulatory status
FDA-approved
This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Abdominal discomfort
- 02Fluid overload risk (teduglutide labeling)
- 03Theoretical growth effects on any neoplasms
Contraindications
None specified.
§ 10 Questions
GLP-2 FAQ
- What is GLP-2?
- Intestinotrophic peptide that stimulates intestinal growth and nutrient absorption; approved analog teduglutide is used in short bowel syndrome. GLP-2 binds the GLP-2 receptor on enteric neurons and subepithelial myofibroblasts, stimulating epithelial proliferation, reducing intestinal permeability, and improving nutrient absorption.
- What is GLP-2 used for?
- Reported uses include intestinal mucosal growth and repair, reduced gut permeability, and adjunct in ibd and gut-recovery protocols. Evidence strength is rated Established — see the evidence section for detail.
- How is GLP-2 dosed?
- Commonly referenced dosing is 500 mcg – 1.5 mg daily (research), administered SubQ. This is educational reference only; consult a licensed clinician before use.
- What are the side effects of GLP-2?
- Commonly reported side effects include abdominal discomfort, fluid overload risk (teduglutide labeling), and theoretical growth effects on any neoplasms. This list is not exhaustive.
- Is GLP-2 legal?
- This compound has an FDA approval for at least one indication. Brand pharmacy channels exist. Compounding may or may not be available depending on shortage status. FDA status: Teduglutide is FDA-approved. Non-analog GLP-2 is not..